Based on our current findings, strategies that could capitalize on the infiltration of double-negative T-cells or conversely enhance CD4+/CD8+ recruitment to the tumor may be beneficial, as may be strategies to dampen the PD-1/PD-L1 axis. The gene discussed is CD274; the disease is neoplasm.